4D Molecular Therapeutics, Inc. Variable Lease, Cost
4D Molecular Therapeutics, Inc. (FDMT) reported Variable Lease, Cost of $678.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $678.00K, a 4.63% increase year-over-year.
- 4D Molecular Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $676.00K, a 11.40% decline year-over-year.
- 4D Molecular Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $670.00K, a 19.43% increase year-over-year.
- 4D Molecular Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $672.00K, a 47.69% increase year-over-year.
- 4D Molecular Therapeutics, Inc. variable lease, cost for fiscal 2025 was $2.76M, a 51.12% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. variable lease, cost for fiscal 2024 was $1.83M, a 47.03% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. variable lease, cost for fiscal 2023 was $1.24M, a 23.17% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. variable lease, cost for fiscal 2022 was $1.01M, a 10.50% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $678.00K 10-Q · filed 2026-08-13 | $1.35M 10-Q · filed 2026-08-13 | $2.02M derived: sum of 3 quarters · filed 2026-08-13 | $2.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $676.00K 10-Q · filed 2026-05-07 | $1.35M derived: sum of 2 quarters · filed 2026-05-07 | $2.02M derived: sum of 3 quarters · filed 2026-05-07 | $2.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $670.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.34M derived: sum of 2 quarters · filed 2026-03-18 | $1.99M derived: sum of 3 quarters · filed 2026-08-13 | $2.76M 10-K · filed 2026-03-18 |
| 2025-09-30 | $672.00K 10-Q · filed 2025-11-10 | $1.32M derived: sum of 2 quarters · filed 2026-08-13 | $2.09M 10-Q · filed 2025-11-10 | $2.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $648.00K 10-Q · filed 2026-08-13 | $1.42M 10-Q · filed 2026-08-13 | $1.97M derived: sum of 3 quarters · filed 2026-08-13 | $2.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $763.00K 10-Q · filed 2026-05-07 | $1.32M derived: sum of 2 quarters · filed 2026-05-07 | $1.78M derived: sum of 3 quarters · filed 2026-05-07 | $2.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $561.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $1.02M derived: sum of 2 quarters · filed 2026-03-18 | $1.37M derived: sum of 3 quarters · filed 2026-03-18 | $1.83M 10-K · filed 2026-03-18 |
| 2024-09-30 | $455.00K 10-Q · filed 2025-11-10 | $809.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.27M 10-Q · filed 2025-11-10 | $1.47M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $354.00K 10-Q · filed 2025-08-11 | $707.00K 10-Q · filed 2025-08-11 | $1.02M derived: sum of 3 quarters · filed 2025-08-11 | $1.33M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $354.00K 10-Q · filed 2025-05-08 | $665.00K derived: sum of 2 quarters · filed 2025-05-08 | $976.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.29M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $311.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $622.00K derived: sum of 2 quarters · filed 2025-02-28 | $933.00K derived: sum of 3 quarters · filed 2025-02-28 | $1.24M 10-K · filed 2025-02-28 |
| 2023-09-30 | $311.00K 10-Q · filed 2024-11-13 | $622.00K derived: sum of 2 quarters · filed 2024-11-13 | $933.00K 10-Q · filed 2024-11-13 | $1.37M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $311.00K 10-Q · filed 2024-08-08 | $622.00K 10-Q · filed 2024-08-08 | $1.06M derived: sum of 3 quarters · filed 2024-08-08 | $1.32M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $486.00K 10-Q · filed 2024-05-09 | $745.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.00M derived: sum of 3 quarters · filed 2024-05-09 | $1.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $519.00K derived: sum of 2 quarters · filed 2024-02-29 | $765.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.01M 10-K · filed 2024-02-29 |
| 2022-09-30 | $260.00K 10-Q · filed 2023-11-09 | $506.00K derived: sum of 2 quarters · filed 2023-11-09 | $751.00K 10-Q · filed 2023-11-09 | $992.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $246.00K 10-Q · filed 2023-08-09 | $557.00K 10-Q · filed 2023-08-09 | $732.00K derived: sum of 3 quarters · filed 2023-08-09 | $952.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $267.00K 10-Q · filed 2023-05-11 | $486.00K derived: sum of 2 quarters · filed 2023-05-11 | $706.00K derived: sum of 3 quarters · filed 2023-05-11 | $947.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $439.00K derived: sum of 2 quarters · filed 2023-03-15 | $680.00K derived: sum of 3 quarters · filed 2023-03-15 | $914.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $220.00K 10-Q · filed 2022-11-08 | $461.00K derived: sum of 2 quarters · filed 2022-11-08 | $695.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $241.00K 10-Q · filed 2022-08-11 | $476.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $219.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |